Glucosylceramidase beta 1 (GBA1)

Glucosylceramidase beta 1 (GBA1) is a critical lysosomal enzyme responsible for the hydrolysis of glucosylceramide into glucose and ceramide, playing a central role in sphingolipid metabolism and cellular membrane turnover (UniProt, 2024). Deficiency in GBA1 activity, typically due to biallelic mutations, leads to Gaucher disease, a lysosomal storage disorder characterized by the accumulation of glucosylceramide in macrophages, resulting in hepatosplenomegaly and bone marrow infiltration (MedlinePlus, 2021). Beyond its role in Gaucher disease, GBA1 is recognized as the most significant genetic risk factor for Parkinson's disease and dementia with Lewy bodies, where reduced enzyme activity is linked to the toxic aggregation of alpha-synuclein (NIH, 2024). Therapeutic interventions include enzyme replacement therapies like imiglucerase for systemic symptoms and substrate reduction therapies like eliglustat to manage lipid buildup (NIH, 2024). Current research is heavily focused on brain-penetrant small molecules, such as the pharmacological chaperone ambroxol and the substrate inhibitor venglustat, to address the neurodegenerative aspects of GBA1-related pathologies (ResearchGate, 2026).

Other names

GlucocerebrosidaseAcid beta-glucosidaseGBAGCaseLysosomal acid glucosylceramidaseGLUCSGTaseAlgluceraseBeta-glucosylceramidase 1

Enzyme replacement therapy (ERT) provides a recombinant version of the deficient enzyme; substrate reduction therapy (SRT) inhibits glucosylceramide synthase to decrease substrate accumulation; pharmacological chaperones stabilize mutant GBA1 to enhance its trafficking to the lysosome.